Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application: Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
January 18, 2018
June 5, 2019
10a78d19-deab-4319-a7fe-ebc2b6b0bb1e
Related Documents
Rare Diseases: Considerations for the Development of Drugs and Biological Products
Guidance DocumentDecember 26, 2023Center for Drug Evaluation and Research
Duchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment Guidance for Industry
Guidance DocumentFebruary 16, 2018Center for Drug Evaluation and Research
Labeling for Human Prescription Drug and Biological Products Approved Under the Accelerated Approval Regulatory Pathway
Guidance DocumentFebruary 4, 2019Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox